Fulcrum Therapeutics, Inc.’s Gross Margin at a glance
Fulcrum Therapeutics, Inc. reports gross margin of 98% for Dec 2024. The prior period recorded 100% (Dec 2023). Year over year the metric moved −2 pts (−2%). The rolling three-period average stands at 86.6%. Data last refreshed Dec 7, 2025, 2:46 AM.
Latest reading
98% · Dec 2024
YoY movement
−2 pts (−2%)
Rolling average
86.6%
Current Gross Margin
98%
−2 pts
−2%
Rolling average
86.6%
Latest Value
98%
Dec 2024
YoY Change
−2 pts
Absolute
YoY Change %
−2%
Rate of change
3-Period Avg
86.6%
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s gross margin stands at 98% for Dec 2024. Year-over-year, the metric shifted by −2 pts, translating into a −2% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How gross margin shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports gross margin of 98%. Measure pricing power and cost of goods efficiency by reviewing historical gross margins.
Pricing versus input costs
Gross margin expands when pricing power or mix more than offset raw material and labor inflation.
Benchmark to peers
Compare margins within a sector to spot operational advantages or signs of discounting.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s gross margin profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current gross margin?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports gross margin of 98%. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s gross margin trending year over year?
Year-over-year, the figure shifts by −2 pts (−2%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does gross margin matter for Fulcrum Therapeutics, Inc.?
Gross margin tracks the percentage of revenue remaining after direct production and service delivery costs. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s gross margin above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at 86.6%. Comparing the latest reading of 98% to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s gross margin refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:46 AM and updates automatically every 24 hours, keeping your valuation inputs current.